| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/27/2002 | EP1009418B1 Robinia pseudoacacia lectin and its uses |
| 03/27/2002 | EP1007534A4 Bh3 interacting domain death agonist |
| 03/27/2002 | EP0934249B1 Conformationally restricted polyamines and their use as antineoplastic agents |
| 03/27/2002 | EP0873336B1 Antagonists of gonadotropin releasing hormone |
| 03/27/2002 | EP0870018B1 Antitumour vector constructs and methods |
| 03/27/2002 | EP0869809B1 Oxidized glutathione as cytokine and hemopoietic factor endogenous production enhancer |
| 03/27/2002 | EP0782452B1 Cell growth regulator |
| 03/27/2002 | EP0730470B1 Improved interferon polymer conjugates |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342196A Bifidobacterium in treatment of inflammatory disease |
| 03/27/2002 | CN1342171A Process for production of multiple cross-linked hyaluronic acid derivatives |
| 03/27/2002 | CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 03/27/2002 | CN1342161A Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 03/27/2002 | CN1342155A Method for high yield extraction of paclitaxel from paclitaxel-containing material |
| 03/27/2002 | CN1342153A Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in production of medicaments |
| 03/27/2002 | CN1342151A 喹啉和喹喔啉化合物 Quinoline and quinoxaline compounds |
| 03/27/2002 | CN1342150A Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors |
| 03/27/2002 | CN1342149A Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| 03/27/2002 | CN1342146A Substituted 1-oxo-and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| 03/27/2002 | CN1342096A Synergistic tumorcidal response induced by histamine |
| 03/27/2002 | CN1342085A Inhibition of differentiation of cytotoxic T-cells by p-selecting ligand (PSGL) antagonists |
| 03/27/2002 | CN1342080A Use of 5-HT5-ligands in treatment of neurodegenerative and neuropsychiatric disturbances |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342073A Antioxidant compositions and methods for companion animals |
| 03/27/2002 | CN1341666A Preparation of active oligosaccharides and their derivatives |
| 03/27/2002 | CN1341662A Scorpion pain-stopping anti-tumor Val-Arg-Gly peptide and its preparation method |
| 03/27/2002 | CN1341658A A novel polypeptide-human cyclin-E conjugated protein (Ceb1) 113-70.07 and polynucleotide for coding said polypeptide |
| 03/27/2002 | CN1341652A A novel polypeptide-human auditory injury related protein 38.39 and polynucleotide for coding said polypeptide |
| 03/27/2002 | CN1341597A Novel anti-tumor active matter bacillosporin P |
| 03/27/2002 | CN1341595A Nonviscous protein type synthetic compound or its carrier combined compound |
| 03/27/2002 | CN1341433A Compound Yanghuo granules |
| 03/27/2002 | CN1341424A Chinese medicine for curing tumor |
| 03/27/2002 | CN1341418A Synergistic type anti-cancer medicine |
| 03/27/2002 | CN1081637C Radiosensitizing diamines and their pharmaceutical preparations |
| 03/27/2002 | CN1081624C Benzamide analogs, useful as PARP (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors |
| 03/26/2002 | US6362336 Administering a quinazoline derivative to a warm-blooded animal for producing an antiangiogenic and/or vascular permeability reducing effect |
| 03/26/2002 | US6362324 Used as target for diagnosis and treatment in aminopeptidase-related disorders such as aging, cancers, cataracts, cystic fibrosis and leukemias; used in drug-screening to identify agonists, antagonists |
| 03/26/2002 | US6362322 Conversion of a watson-crick DNA to a hoogsteen-paired duplex |
| 03/26/2002 | US6362227 Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen |
| 03/26/2002 | US6362217 Antitumor agents |
| 03/26/2002 | US6362210 Carboxylic acid amides, pharmaceutical compositions containing these compounds and their use |
| 03/26/2002 | US6362200 Antitumor dibenzofluorene derivatives |
| 03/26/2002 | US6362195 Inhibitor of nitric oxide synthase; central nervous system disorders |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362188 Farnesyl protein transferase inhibitors |
| 03/26/2002 | US6362164 Combination of a somatostatin analogue and a rapamycin |
| 03/26/2002 | US6362007 For diagnosis and therapy of systemic lupus erythematosus and related diseases, and diseases in which epstein-barr virus has been implicated |
| 03/26/2002 | US6362001 Establishing a culture of drosophila cells; transfecting with expressible class 1 mhc heavy chain gene linked to promoter; transfecting with an expressible .beta.-2 microglobulin gene and with assisting molecule gene, mixing with peptide |
| 03/26/2002 | US6361938 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 03/26/2002 | US6361775 Compositions and methods for vaccines comprising α-galactosyl epitopes |
| 03/26/2002 | US6361771 Implantable cell culture device comprising semipermeable membrane permitting diffusion of growth factor therethrough, and arpe-19 cells genetically engineered to produce growth factor disposed within semipermeable membrane |
| 03/26/2002 | US6361770 Introducing ex vivo nucleic acid molecule comprising sequence encoding tap-1 into tumor cell, expressing tap-1 in tumor cell, permitting recognition of tumor by mammal's immune response, introducing tumor cell into mammal |
| 03/26/2002 | US6361769 Stimulation of host defense mechanisms against viral challenges |
| 03/26/2002 | CA2234249C Therapeutic diet for dogs with lymphoma |
| 03/26/2002 | CA2180570C Isolated p27 protein and its encoding nucleic acid molecules |
| 03/21/2002 | WO2002023784A2 Cysteine protease inhibitors |
| 03/21/2002 | WO2002023190A2 Methods and products related to low molecular weight heparin |
| 03/21/2002 | WO2002022885A1 Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
| 03/21/2002 | WO2002022851A2 Novel tumor-associated marker |
| 03/21/2002 | WO2002022848A2 Compositions comprising mixtures of human cytokines and methods of producing the same |
| 03/21/2002 | WO2002022819A2 Calcium binding proteins |
| 03/21/2002 | WO2002022812A1 Methods of assaying or screening compound via detection of nuclear transport receptor inhibition by hepatitis c virus core protein |
| 03/21/2002 | WO2002022808A2 Cripto mutant and uses thereof |
| 03/21/2002 | WO2002022806A2 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022795A2 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | WO2002022790A1 T cell receptor transfer into a candidate effector cell or a precursor thereof |
| 03/21/2002 | WO2002022777A2 Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses |
| 03/21/2002 | WO2002022687A2 Viral chemokine-tumur antigen fusion proteins |
| 03/21/2002 | WO2002022686A2 Defensin-antigen fusion proteins |
| 03/21/2002 | WO2002022685A2 Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| 03/21/2002 | WO2002022684A2 Transporters and ion channels |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022659A2 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 03/21/2002 | WO2002022655A1 Glutathione conjugates with distamycin derivatives having antitumoral activity |
| 03/21/2002 | WO2002022648A2 Compositions and methods for inducing specific cytolytic t cell responses |
| 03/21/2002 | WO2002022642A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| 03/21/2002 | WO2002022635A1 Antisense modulation of clusterin expression |
| 03/21/2002 | WO2002022626A1 Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds |
| 03/21/2002 | WO2002022618A1 Method for preparing camptothecin and its derivatives |
| 03/21/2002 | WO2002022616A2 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022615A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022598A1 Quinolinone derivatives as tyrosine kinase inhibitors |
| 03/21/2002 | WO2002022597A1 N-phenyl-2-pyrimidine-amine derivatives |
| 03/21/2002 | WO2002022592A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | WO2002022585A1 Tetrahydroquinoline compounds |
| 03/21/2002 | WO2002022577A2 Hydroxamate derivatives useful as deacetylase inhibitors |